MEMO Therapeutics raises CHF 5 million in Series A2 Financing Round

22 May 2018

VISCHER advises Memo Therapeutics, a Basel based spin-off company from the ETH Zurich, whose proprietary MemoMABTM technology constitutes a disruptive platform technology for antibody discovery. This technology allows to create an authentic copy of whole antibody repertoire of human and animal species in recombinant form. 

The CHF 5 million Series A2 financing round was led by Redalpine, Schroder Adveq, investiere.ch and other Swiss investors. The proceeds will be used to further develop the proprietary MemoMABTM technology and to progress MEMO Therapeutics' antibody candidates in the fields of immuno-oncology and infectious diseases towards clinical trials. 

The team at VISCHER was led by Matthias Staehelin (Partner) and supported by Dania Salvisberg-Schneider (Senior Associate), both Corporate.